Tumor-Agnostic Biomarkers and Targeted Treatment of Advanced Colorectal Cancer

Download this slideset for expert perspectives on best practices in testing for tumor-agnostic and CRC-specific biomarkers—including MSI/MMR, TMB, NTRK fusions, BRAF/RAS mutations, and HER2 amplifications—and use of related targeted therapeutics.
John L. Marshall, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.01 MB
Released: June 3, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Bayer HealthCare Pharmaceuticals Inc.
Daiichi Sankyo, Inc.
Seagen Inc.
Turning Point Therapeutics, Inc.

Related Content

Nina Beri, MD reviews ongoing clinical trials in targeted therapies for patients with cholangiocarcinoma presented at ASCO 2022, from Clinical Care Options (CCO)

person default Nina Beri, MD Released: August 3, 2022

Downloadable slideset on therapies for previously treated advanced HER2-negative gastric/GEJ cancers, from Clinical Care Options (CCO)

Samuel Klempner, MD Released: July 21, 2022

Downloadable slideset on therapies for untreated advanced HER2-negative gastric/GEJ cancers, from Clinical Care Options (CCO)

Yelena Y. Janjigian, MD Released: July 21, 2022

Commentary on evolving treatment paradigms in gynecologic cancers, from Clinical Care Options (CCO)

David Scott Miller, MD, FACOG, FACS
Program Director
Nicoletta Colombo, MD Shannon N. Westin, MD, MPH
Released: July 14, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings